ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 521

Subcutaneous Adipose Tissue from Rheumatoid Arthritis Patients Is Characterized By an Abundance of Macrophages That Are Associated with Autoantibodies, Systemic Inflammation, and Immunomodulation

Jon T. Giles1, Anthony W Ferrante2, Rachel Broderick3, Afshin Zartoshti4, Janine Rose3, Hui-Zhu Zhang3 and Robert Winchester3, 1Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 2Endocrinology, Nutrition, and Preventive Medicine, Columbia University, College of Physicians & Surgeons, New York, NY, 3Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 4Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: adipose tissue, immune activation, macrophages and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Adipose tissue macrophages (ATMs) are a potent source of inflammatory cytokines with profound effects on adipose tissue function and systemic inflammation, yet their potential role in rheumatoid arthritis (RA) pathobiology is unstudied.

Methods: Periumbilical subcutaneous adipose tissue was obtained from 36 RA patients and 22 non-RA controls frequency matched on demographics and body mass index (BMI).  Individuals with diabetes were excluded.  Samples were stained for the macrophage marker CD68 and the average proportion of ATMs relative to total nucleated cells was compared between groups.  Using real time polymerase chain reaction (RT-PCR), gene expression profiles for selected inflammatory cytokines, chemokines, and macrophage markers were assessed and their correlations with RA disease characteristics were explored.

Results: The RA and control groups were well matched [mean age=54 years, 75% female, mean BMI=28.1].  Median RA duration was 6.3 years and 77% were seropositive for rheumatoid factor (RF) or anti-CCP antibodies. A total of 78% were treated with non-biologic DMARDs, 44% with biologics, and 25% with prednisone.  The proportion of ATMs was 76% higher in RA vs. non-RA samples (37.7 vs. 21.3%, respectively; p<0.001).  ATMs aggregated into crown-like structures (CLSs) around adipocytes were more than 1.5-fold higher in the RA group compared with controls (0.58 vs. 0.23 CLSs/high-power field, respectively; p=0.001).  ATMs were significantly more abundant in early RA and in those seropositive for anti-CCP (Fig1A&B).  Users of methotrexate, leflunomide, and TNF inhibitors had a significantly lower proportion of ATMs compared with non-users (Fig1C&D).  Average CLSs were significantly higher among those with RF (48% higher; p=0.038) or a serum CRP≥10 mg/L (112% higher; p=0.001).  Adipose expression of IL-6, MCP-1, MMP-9, osteopontin, C1q, and the macrophage markers CD64, CD68, and CD163 were all significantly associated with serum CRP, IL-6, DAS28 score, and duration of morning stiffness, all with Spearman correlation coefficients ranging between 0.3 and 0.7 and p-values<0.05.  In a multivariable linear regression model predicting serum CRP; gender, biologic use, swollen joints, RF and/or anti-CCP seropositivity, BMI, and adipose MCP-1 expression level accounted for 63% of the explainable variability.  Of this variability in CRP, adipose expression of MCP-1 independently accounted for 11% whereas swollen joints only accounted for 5%.

Conclusion: ATMs were more abundant in RA and associated with systemic inflammation and autoantibody status, suggesting possible contributions to the RA disease process.  Lower levels of ATMs associated with specific RA treatments suggest that adipose tissue inflammation may be ameliorated by immunomodulation.


Disclosure: J. T. Giles, None; A. W. Ferrante, None; R. Broderick, None; A. Zartoshti, None; J. Rose, None; H. Z. Zhang, None; R. Winchester, None.

To cite this abstract in AMA style:

Giles JT, Ferrante AW, Broderick R, Zartoshti A, Rose J, Zhang HZ, Winchester R. Subcutaneous Adipose Tissue from Rheumatoid Arthritis Patients Is Characterized By an Abundance of Macrophages That Are Associated with Autoantibodies, Systemic Inflammation, and Immunomodulation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/subcutaneous-adipose-tissue-from-rheumatoid-arthritis-patients-is-characterized-by-an-abundance-of-macrophages-that-are-associated-with-autoantibodies-systemic-inflammation-and-immuno/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneous-adipose-tissue-from-rheumatoid-arthritis-patients-is-characterized-by-an-abundance-of-macrophages-that-are-associated-with-autoantibodies-systemic-inflammation-and-immuno/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology